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Abstract
Colorectal cancer (CRC) is one of the leading causes of deaths in the United States. Roughly 150,000 new
cases are diagnosed each year, resulting in ~50,000 deaths. About 10-30% of CRC patients harbor either
loss of or missense mutations in SMAD4, a critical component of the TGF-β signaling pathway. Our lab
and others have shown that complete loss of Smad4 results in the increase in tumor size, microvascular
density, and frequency of metastasis in CRC xenograft models. While the role of Smad4 loss in CRC
progression has been extensively studied, the pathophysiological function of missense mutations in
Smad4 is not fully understood. At the molecular level, these mutations usually map to the MH2 domain
and eliminate residues that are involved in the formation of the heteromeric complex with regulatory
Smads (R-Smads) such as Smad2/3 and ensuing transcriptional activation. These detrimental effects
suggest that SMAD4 missense mutations can be categorized as loss-of-function (LOF). However,
uncharacteristically for LOF mutations, they cluster in a few hotspots (e.g., R361), which is more
consistent with a gain-of- or neomorphic function. Here, we investigated the functional role of Smad4
R361 mutants in vitro by re-expressing two R361 Smad4 variants in Smad4-null CRC cells. As predicted,
R361 mutations disrupted Smad2/3-Smad4 heteromeric complex formation and abolished canonical
TGF-β downstream signaling. In that, they were similar to SMAD4 loss. However, RNA sequencing and
subsequent RT-PCR revealed that Smad4mut cells possess the known gene signature associated with
enhanced LEF1 protein function and increased WNT signaling. Mechanistically, Smad4 mutant proteins
retained binding to LEF1 protein and directed a commensurate increase in downstream Wnt signaling as
measured by TOP/FOP luciferase assay. Consistent with these findings, human CRCs with SMAD4
missense mutations were less likely to acquire activating mutations in the key Wnt pathway gene
CTNNB1 (encoding beta catenin) than CRCs with truncating SMAD4 nonsense mutations. The former was
also associated with shorter survival. Collectively, these studies implicate a TGF-β ligand-independent
gain of function role for mutant Smad4 in CRC.
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ABSTRACT
SMAD4 WITH R361 HOTSPOT MUTATIONS RETAINS THE ABILITY TO BIND
TO LEF1 AND BOOSTS WNT SIGNALING IN COLORECTAL CANCER CELLS
Claudia B Lanauze Torres
Andrei Thomas-Tikhonenko
Colorectal cancer (CRC) is one of the leading causes of deaths in the United
States. Roughly 150,000 new cases are diagnosed each year, resulting in ~50,000
deaths. About 10-30% of CRC patients harbor either loss of or missense mutations in
SMAD4, a critical component of the TGF-β signaling pathway. Our lab and others have
shown that complete loss of Smad4 results in the increase in tumor size, microvascular
density, and frequency of metastasis in CRC xenograft models. While the role of Smad4
loss in CRC progression has been extensively studied, the pathophysiological function of
missense mutations in Smad4 is not fully understood. At the molecular level, these
mutations usually map to the MH2 domain and eliminate residues that are involved in the
formation of the heteromeric complex with regulatory Smads (R-Smads) such as Smad2/3
and ensuing transcriptional activation. These detrimental effects suggest that SMAD4
missense mutations can be categorized as loss-of-function (LOF). However,
uncharacteristically for LOF mutations, they cluster in a few hotspots (e.g., R361), which
is more consistent with a gain-of- or neomorphic function. Here, we investigated the
functional role of Smad4 R361 mutants in vitro by re-expressing two R361 Smad4 variants
in Smad4-null CRC cells. As predicted, R361 mutations disrupted Smad2/3-Smad4
heteromeric complex formation and abolished canonical TGF-β downstream signaling. In
that, they were similar to SMAD4 loss. However, RNA sequencing and subsequent RTPCR revealed that Smad4mut cells possess the known gene signature associated with
enhanced LEF1 protein function and increased WNT signaling. Mechanistically, Smad4
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mutant proteins retained binding to LEF1 protein and directed a commensurate increase
in downstream Wnt signaling as measured by TOP/FOP luciferase assay. Consistent with
these findings, human CRCs with SMAD4 missense mutations were less likely to acquire
activating mutations in the key Wnt pathway gene CTNNB1 (encoding β-catenin) than
CRCs with truncating SMAD4 nonsense mutations. The former was also associated with
shorter survival. Collectively, these studies implicate a TGF-β ligand-independent gain of
function role for mutant Smad4 in CRC.
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CHAPTER 1: GENERAL INTRODUCTION
OVERVIEW
Colorectal Cancer (CRC) is the second most common cause of cancer death in
the United States. Early-stage CRC is successfully treated by surgical intervention;
however, relapse can occur even if the primary tumor was successfully removed during
the initial treatment. Reemergence of colorectal cancer usually leads to metastasis, often
resistant to the current chemotherapy regimen. Patients diagnosed with localized disease
have about a 90% 5-year survival rate, compared to those diagnosed with metastatic
CRC, which have only 14% 5-year survival rate1. Therefore, elucidating molecular events
that lead to the advancement of CRC could open the door for future targeted therapies for
such patients.
About 10-30% of CRC patients harbor some loss of Smad4, a critical component
of the TGF-β signaling pathway, either by deep deletion or missense mutations 2. Based
on limited research, naturally occurring Smad4 mutations are thought to be loss-offunction. However, there is a big gap in our understanding of the role of mutant Smad4 in
TGF-β signaling in CRC progression or any other acquired novel function, if any. Here, we
provide relevant background information important to understand potential role of TGF-β
signaling to CRC progression.

COLORECTAL CANCER (CRC)
In 2020, almost 148,000 individuals will be diagnosed with CRC and over 53,000
will die from the disease. The majority of CRC cases occur in individuals 50 years of age
or older, however, up to 12% of newly diagnosed CRC cases are attributed to individuals
younger than 50 years1. Although 10% of patients with CRC have a genetic predisposition
to the disease, the majority of CRC cases are sporadic.
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Benign GI tumors are a varied group but localized lesions that project above the
surrounding tissue are commonly termed polyps. Although some polyps (termed
hyperplastic polyps – polyps less than 5mm in size) are not a major precursor of CRC, the
adenomatous polyp (adenoma) is thought to be the most important precursor lesion2. Even
though only a fraction of adenomas will progress to cancer, there is a risk of CRC in
individuals whose adenomas are not removed, and polypectomy decreases the risk of
CRC 3,4.

Figure 1. Molecular Events in CRC
In the ‘classic’ CRC formation model originally developed by Dr. Bert Vogelstein
(Figure 1), CRC pathogenesis occurs due to the progressive accumulation of genetic and
epigenetic alterations. The loss of genomic stability accelerates the accumulation of
mutations in oncogenes and tumor suppressor genes. This creates a clonal growth
advantage that leads to the outgrowth of malignant cells, which can ultimately develop into
invasive adenocarcinoma5–7. Although some specific genetic events have been described
as initiating events for CRC, the progressive accumulation of the alterations, rather than
the order, seems to be key for the progression of colorectal tumors6.
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At least two major genomic pathways are involved in the origin and progression of
CRC: microsatellite instability (MSI) and chromosomal instability (CIN). About 15% of
CRCs occur due to microsatellite instability (MSI), a genetic event that causes hyper
mutability in the DNA as a result in loss of functional DNA mismatch repair genes (MMR) 8.
Most commonly, the promoter of hMLH1 will be hypermethylated, resulting in gene
silencing9. In some instances, MSI can occur at protein-coding sequences that eventually
result in point or frame-shift mutations that will yield a truncated, nonfunctional protein 10.
In these tumors, frequent inactivating mutations (~85% of colorectal tumors) occur to the
transforming growth factor beta receptor 2 (TGFβRII) 11 gene, a critical component of the
transforming growth factor beta (TGF-β) signaling family.
Chromosomal instability (CIN) represents 85% of sporadic CRCs12 and is
characterized by allelic losses, amplifications, and translocations; usually associated with
mutations in tumor suppressor genes or oncogenes 13. This process involves the alteration
of several pathways including the WNT pathway through the loss of APC, the addition of
constitutive active mutations in KRAS or BRAF, mutations in the PI3K pathway, and
inactivation of SMAD4 and TP53. Specifically:
1. Adenomatous polyposis coli (APC) gene and WNT signaling pathway:
Approximately 80% of all sporadic colorectal adenomas and carcinomas have
somatic mutations that inactivate the tumor suppressor APC, a major binding
partner and regulator of β-catenin in the canonical WNT signaling pathway3,14.
Briefly, APC binds and collaborates with other proteins to form the β-catenin
destruction complex, which ubiquitinates and targets β-catenin for proteasomal
degradation15. APC inactivation will primarily result in the stabilization of β-catenin,
which mimics constitutively active WNT signaling16.
2. Mutations affecting the TGF-β pathway components in CRC: loss of
heterozygosity (LOH) of chromosome 18q is observed more than 70% of CRCs 17.
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Two chromosome 18q tumor suppressor genes, SMAD2 and SMAD4, encode
proteins that function downstream of the TGF-β receptor complex18,19. Mutations
that inactivate SMAD4 are found in ∼10–15% of CRCs, and SMAD2 inactivating
mutations are found in ∼5% of CRCs. Mutations inactivating the SMAD3 gene,
which maps to chromosome 15, are also only found in ∼5% of CRCs 3,20–22.
3. Alterations in the KRAS, BRAF, PIK3CA and PTEN signaling pathway: Ras
family is comprised of a group of small GTP-binding proteins that regulate different
signaling pathways involved in cell proliferation, differentiation, migration, survival
and apoptosis23. Active Ras can bind to a variety of effector proteins, the best
characterized being Ras kinases24 and phosphatidylinositol 3-kinases25 (PI3-K).
It’s three members, KRAS, HRAS and NRAS are common targets for somatic
mutations in human cancers23. KRAS somatic mutations are found in up to a half
of CRC patients. The vast majority of mutations affect codon 12 and contribute to
colorectal adenoma development17,26. Mutations of RAS are clinically relevant
given that their presence interferes with the response of monoclonal antibodies
against epidermal

growth

factor

receptor (EGFR)

like

cetuximab and

panitumumab27,28.

Six research groups identified a consensus for gene expression based on a
subtyping classification system for CRC, which resulted into four consensus molecular
subtypes (CMS). The four CMS subtypes identified (CMS1- CMS4) differ in genetic and
epigenetics, as well as the signaling pathways they follow. While CMS1 is characteristic
of tumors with MSI, tumors with CIN can be subclassified based on gene expression:
CMS2 (canonical subtype), CMS3 (metabolic subtype) and CMS4 (mesenchymal
subtype)29.
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Around 14% of all CRCs are classified into the CMS1 subtype, from which the
majority of patients (88%) have inherited disease and remaining 12% are sporadic (noninherited) CRCs29. They are also defined by having high BRAF V600E mutation rate30 and
a widespread hypermethylation status, resulting in loss of tumor suppressor function. Out
of the four subgroups, CMS1 tumors show marked upregulation of proteins involved in
immune response pathways12,29.
The CMS2 (canonical) subtype accounts for the largest number of CRC patients,
with about 39%29. There are more frequent copy number losses in tumor suppressor
genes and copy number gains in oncogenes in CMS2 compared to other subtypes.
Thought to arise from the canonical adenoma-to-carcinoma pathway, the gene expression
profile in CMS2 is often characterized by having hyperactive Myc and WNT/β-catenin
signal transduction pathways29,31. CMS3 subtype, also known as the metabolic subtype,
accounts for 37% of CRCs. Although KRAS mutations are present in every CRC subtype,
they are significantly enriched in this subtype. CMS3 displays prominent metabolic
activation, a hallmark that can prove useful for specific future targeted therapies31. Finally,
CMS4 is defined by having microsatellite stable (MSS) CRC tumors. Tumors show
upregulation of genes involved in EMT and it has signatures associated with the activation
of TGF-β signaling. In addition, samples from CMS4 subtype have significant
overexpression of proteins involved in angiogenesis, matrix remodeling pathways and the
complement-mediated inflammatory system29,32. Overall, these specific subtypes can help
determine treatment strategies for individual CRC patients, based on the mutation panel
and activated pathways in their tumors.
TGF-β and WNT pathways do not work in isolation, as there are examples of
known interactions between them in cancer. β-catenin, the main effector of WNT signaling,
has been found to form complexes with Smad proteins to enhance β-catenin protein
stability and facilitate its transcriptional activity in chondrocytes33. The WNT effector LEF1
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has been shown to co-occupy the CDH1 (E-cadherin) promoter with SMAD proteins,
providing a molecular mechanism for the observed cooperation of WNT and TGF-β in
EMT34. For the next sections of this introduction, we focus on describing TGF-β and WNT
signaling pathways and their deregulation in colorectal cancer, as it pertains to the
understanding of this study.

TRANSFORMING GROWTH FACTOR β (TGF-β) SUPERFAMILY SIGNALING
OVERVIEW
The transforming growth factor beta (TGF-β) is a family of secreted polypeptide
growth factors which include TGF-βs, activins, nodals, bone morphogenic proteins (BMPs)
and others that play an important role in a variety of cellular processes such as cell growth,
differentiation, migration and apoptosis35.
The TGF-β signaling pathway is activated by TGF-β ligands (TGFβ1, β2, and β3),
which bring together receptor type I and type II (RI and RII), both serine/threonine kinase
receptors. Upon receptor dimerization, type II receptors phosphorylate and activate type I
receptors. Following receptor phosphorylation and activation, type I receptor kinase will
directly phosphorylate the receptor-regulated Smads (R-Smads) on the last two serine of
a conserved specific phosphorylation motif, SSXS, located at the extreme carboxyl
terminus of the MH2 domain36.
The TGF-β ligand will phosphorylate Smad2 and 3 while BMP ligand and receptors
will activate Smad1, 5 and 8. Once activated, R-Smads will form a complex with Smad4,
also known as common mediator Smad. Once the complex forms, it will translocate into
the nucleus, bind to DNA and other transcription factors where it will modify a different set
of target genes37,38.
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TGFβRII receptors not only induce Smad-mediated responses but also activate
Smad-independent responses, which allow additional versatility and diversification of
TGF-β family responses. The non-Smad pathways include, but are not limited to, the
activation of other mediators such as those involved in the Erk, JNK, and p38 MAPK
kinase pathways39 (Figure 2).

Figure 2. Smad-dependent and Smad-independent TGF-β signaling

SMAD PROTEINS AS EFFECTORS OF TGF-β
The eight-known Smads are around 500 amino acids in length and are divided into
three classes according to their function. The receptor regulated Smads, or R-Smads, are
direct substrates corresponding to their receptors. As mentioned above: Smad1, 5, and 8
serve principally as substrates for BMP receptors, and Smad2 and 3 for the TGF-β
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receptors. The common mediator Smad (co-Smad), Smad4, participates in TGF-β by
binding to R-Smads. Lastly, there are inhibitor Smads or I-Smads, which includes Smads
6 and Smad7: they antagonize TGF-β signaling by interfering with Smad-receptor or
Smad-Smad interactions35. Smad7 can inhibit both TGF-β and BMP, whereas Smad6
preferentially inhibits BMP signaling40,41.
Smad proteins are composed of two globular domains, joined together by a
proline-rich linker region. The Mad homology 1 (MH1) domain, located at the N-terminus,
is highly conserved among all R-Smads and Smad4, but not Smad6 and 7. The MH1
domain, which contains a β-hairpin structure, functions as a DNA-binding domain. The
most abundant isoform of Smad2 contains a 30-amino acid insertion encoded in exon 3,
which is thought to displace the β-hairpin loops, blocking its ability to bind to DNA 42,43. A
splice variant of Smad2 which lacks exon 3 (Smad2Δ3) binds to DNA equivalently to
Smad344. Smad3 and Smad4 recognize a specific sequence in the DNA called the Smadbinding element (SBE), which is defined as GCTC or its reverse complement, AGAC 43.
The MH1 domain is followed by a linker region, which contains several important
peptide motifs including phosphorylation sites for several classes of protein kinases
including MAPKs and CDKs35,45. R-Smads and I-Smads also contain a conserved prolinetyrosine (PY) motif that mediates interaction with the WW domains in the Smad-interacting
proteins Smurf1 and Smurf 2. Smurfs are E3 ubiquitin ligases of the C2-WW-HECT
domain class that catalyze ubiquitin-mediated degradation of certain Smads and Smadassociated proteins, including nuclear oncoprotein SnoN and the TGF-β-receptor
complex46–48. The linker region in Smad4, however, contains a CRM1 recognized nuclear
export signal (NES)49 and also part of the Smad activation domain (SAD)50, which is
required for transcriptional activation.
The Smad MH2 domain is highly conserved among all Smads and is responsible
for receptor recognition in the case of R-Smads, transactivation, interaction with
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transcription factors and Smad-Smad oligomerization51–53 (Figure 3). A crystal structure
for Smad4 revealed that Smad4 hetero-oligomerizes with Smad2 through a defined L3
loop in the MH2 domain53 and several Smad-inactivating mutations found in tumors map
to the MH2 domain interface and inhibit Smad oligomer formation 54, including mutation
hotspot region in CRC in Smad4 (Asp351-Pro356, Arg36) that is involved in binding to
R-Smads55.

Figure 3. Smad proteins and their structural elements
As stated above, activated Smad complexes accumulate in the nucleus, where
they bind DNA directly or indirectly via other transcription factors and then regulate
expression of different target genes. Smads interact with co-activators including p300 and
CBP which have histone acetyl transferase (HAT) activity56. This interaction is mediated
by the Smad activation domain in R-Smads and Smad4 (located within the linker and MH2
domain) and is essential for maximal transcriptional activation57. Smads can also bind
proteins that will repress Smad-dependent transcription, most famously Ski and SnoN
proteins. Because the Ski binding surface on Smad4 overlaps with that required for
binding of R-Smads, Ski and R-Smads compete for mutual exclusive binding to Smad4,
leading to disruption of functional Smad4-R-Smad complexes58. Overall, binding of Smads
to specific transcription factors allow for a variation in TGF-β functions.
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COMMON MEDIATOR SMAD – SMAD4
As previously mentioned, Smad4 is referred to as the common mediator Smad due
to it being a central mediator for both TGF-β and BMP signaling59. It is composed of 552
amino acids (~60kDA) and its primary structure consists of three major parts, including
the N-terminal MH1 domain, the C-terminal MH2 domain and the linker region in between
them35. Smad4 forms a complex with Smad2 and Smad3, and translocate to the nucleus
where it activates transcription of multiple TGF-β response genes35,36,49,53. Smad4 is an
important component of the TGF-β signaling pathway and plays a critical role in its tumor
suppressive role, mainly by inducing cell cycle arrest and apoptosis. For example, Smad4
can induce p21CIP expression by binding to its promoter, resulting in inhibition of cell
proliferation60,61.

TGF-β SIGNAING IN CANCER
TGF-β signaling plays a dual role in cancer progression. In normal and
premalignant cells, TGF-β acts as a tumor suppressor by inhibiting cell growth and
inducing apoptosis. For example, Smad transcriptional complexes can target p15INK4b
and p21CIP62,63 for transcriptional activation leading to cyclin-dependent kinase (CDK)
inhibition and subsequent cell cycle arrest. Interestingly, the proto-oncogene c-Myc can
block TGF-β induced growth arrest64. Smad3 can directly bind to a TGF-β inhibitory
element (TIE) in the promoter of c-myc and repress its transcription 65, leading to
subsequent downregulation of c-Myc and upregulation of p21CIP66 and p15INK4b67.
Even though TGF-β/Smad signaling can inhibit cell proliferation and induce
apoptosis in non-cancerous cells, TGFβ1 mRNA is highly expressed within tumor tissues
of many cancer types68. For example, CRC patients with high levels of TGF-β are
associated with a high risk of cancer recurrence compared to those with low levels of TGF-
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β in their tumors69. This is because during the later stages of cancer, TGF-β acts as a
tumor promoter by inducing tumor invasion and metastasis, which can be done through
modulation of the surrounding tumor microenvironment. As an illustration, when CRCderived cell lines are engineered to secret active TGFβ1, they display increased
metastasis in mice to both liver and lung. This event was found to be mainly driven by
TGF-β activation in tumor-associated stromal cells69.
An important effect of TGF-β on tumor progression is the induction of epithelial to
mesenchymal transition (EMT), wherein epithelial-like tumor cells generate mesenchymallike characteristics, including decreased cell-cell adhesion and increased migration,
invasion, and apoptosis-resistant properties70,71. TGF-β, among other tumor-associate
growth factors, is responsible for the induction of multiple EMT-inducing factors including
Snail, Slug, ZEB and Twist70. TGF-β regulates EMT through Smad-dependent and Smadindependent pathways, such as PI3K/Akt, ERK1/2, p38 and MAPK. For example:
1. Smad-dependent pathway EMT: Downregulation of Smad2 or SARA (Smad
anchor for receptor activation; an endocytic adaptor protein that facilitates
Smad2 binding to the TGFβRI and phosphorylation) increases the induction of
EMT in human renal epithelial cells72. Also, ubiquitination of Smad4 by the E3
ubiquitin ligase TIF1γ disrupted nuclear Smad complex, antagonizing TGF-βinduced EMT in human mammary epithelial cells 73.
2. Smad-independent pathway EMT: On the other hand, TGF-β receptors can
directly influence EMT via post-translational modifications of regulators of
epithelial cell polarity and tight-junction assembly as is the case with Par6
protein. TGFβRII will phosphorylate Par6, which in turn recruits Smurf1, an E3
ubiquitin ligase. Smurf1 will then target RhoA for ubiquitination and
degradation, resulting in loss of tight junctions and cell polarity 74,75. Recent
studies have also shown that TGF-β activates mTOR pathway during EMT via
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PI3K and Akt76. The activation of mTOR, in turn, contributes to increased
mRNA expression of transcription factor Snail which leads to changes in
migration and invasion77.

Among other processes that TGF-β can control is angiogenesis, the process by
which new blood vessels form from pre-existing blood vessels. Tumors can co-opt this
mechanism and use it to their advantage, allowing for increased nutrients and oxygen
supply78. For many tumors, increased vascularity can result in metastasis as the new blood
vessels provide a route by which tumors cells exit the primary tumor site and enter the
circulation79. Vascular density can provide a prognostic indicator of metastatic potential,
with the highly vascular primary tumors having higher incidence of metastasis than poorly
vascularized tumors80. For example, our lab has shown that downregulation of Smad4
protein in colorectal cancer cells results in increased angiogenesis in vivo, due to
downregulation of antiangiogenic factor CTGF81.

ALTERATIONS OF SMAD4 IN CANCER
Malignant cells can circumvent the suppressive effects of TGF-β either through
inactivation of core components of the pathway, such as the receptors or by downstream
alterations that disable the tumor suppressive arm the pathway37. Smad4 is an essential
signal transducer of the transforming growth factor β (TGF-β) signaling pathway and is
described as a tumor suppressor. Loss of Smad4 expression promotes malignancy in
colorectal cancer tumors cells82 and serves as a prognostic marker in colorectal cancer
patients83–85.
Furthermore, Smad4 mutations are associated with the occurrence of JPS 86 and
mutations or deletions have been found in about half of pancreatic cancers as well as
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approximately 10-30% of colorectal cancers2,87. In these tumors, Smad4 mutations appear
more frequently in the MH2 domain and may be missense or nonsense mutations 88. The
reported nonsense mutation found in PDAC at amino acid 515 results in an unstable
protein89 while missense mutations have been reported to affect the ability of Smad4 to
form complexes with R-Smads in vitro90. Mutations found at the MH1 domain affect protein
stability due to a higher susceptibility to ubiquitin-mediated degradation and they can also
affect DNA binding or nuclear translocation91,92. Finally, there is a strong correlation
between high frequency of Smad4 inactivation (either by deletions or point mutations) and
distant metastasis in colorectal cancer 93–95.

WNT PATHWAY OVERVIEW AND DEREGULATION IN CRC
The WNT pathway is commonly divided into β-catenin dependent (canonical) and
independent (non-canonical) signaling. For this thesis, we will focus on describing and
understanding the canonical WNT signaling pathway.

Figure 4. Canonical Wnt/β-catenin dependent signaling pathway
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The canonical WNT/β-catenin signaling pathway plays different cellular roles
including regulating cellular proliferation, differentiation, tissue homeostasis and repair,
and cellular apoptosis96. In the absence of WNT ligands (WNT-inactive state), β-catenin
is phosphorylated by the destruction complex which leads to its subsequent ubiquitination
and proteasomal degradation. The destruction complex contains scaffold protein Axin
(which contains binding domains for β-catenin), tumor suppressor gene APC and the
kinases GSK3β and casein kinase 1 (CK1) 14. When in complex, β-catenin will be
phosphorylated at Ser45 by CK1, followed by phosphorylation at Ser33, Ser37 and Thr41
by GSK3β15,97,98. Phosphorylated β-catenin will be recognized and ubiquitinated by E3
ligase β-TrCP 99–101 and targeted for degradation. Of note, the phosphorylation sites in βcatenin are contained within the N-terminal domain, which is hotspot for mutations in
cancers102–104.
In a WNT-active state, secreted WNT ligands will bind to Frizzled (Fzd) receptors
and LRP5-6 co-receptors. LRP receptors will be phosphorylated by CK1 and GSK3β,
which recruits Dishevelled (Dvl) proteins to the plasma membrane, where they polymerize
and are activated14. This will ultimately result in the dissociation of the destruction complex,
which allows β-catenin stabilization and translocation into the nucleus. There, β-catenin
forms an active complex with lymphoid enhancer-binding factor 1 (LEF1) and T-cell factor
(TCF) proteins and a host of co-activators to drive transcription of target genes105.
Because it has no intrinsic ability to bind to DNA, β-catenin relies on DNA-binding factors
to regulate gene expression106. Just like with the TGF-β signaling pathway, transcription
of genes driven by WNT activation vary and depends on cell type96.
As mentioned in the beginning sections of this introduction, mutations in
components of the canonical WNT signaling pathway occur in the majority of colorectal
cancers with inactivating mutations in APC being most common. Mutations of APC were
first identified in the germline of patients with familial adenomatous polyposis (FAP), a
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hereditary condition that predisposes patients to intestinal polyps 107. In colorectal cancer
tumors, both alleles at the APC locus are affected by point mutations that can lead to stop
codons or frameshifts leading to the deletion of the C-terminal half of the protein 14. These
mutations typically remove the interaction sites with Axin, leading to the inappropriate
assembly of the β-catenin destruction complex16. β-catenin, however, is mutated in a small
percentage of colorectal carcinomas (around 10%) 14,108. The mutations affect specific
serine and threonine residues which are essential for the targeted degradation of βcatenin109.

LEF1 TRANSCRIPTION FACTOR FAMILY
Because LEF1 is a key transcription factor downstream WNT signaling, we will
detail the role of LEF1 protein in WNT signaling for the remainder of this section. LEF1
belongs to the T cell factor (TCF)/LEF family of transcription factors, containing a highly
conserved high mobility group (HMG) DNA-binding domain and plays a role of nuclear
effects in the WNT/β-catenin pathway110. In the absence of nuclear β-catenin, LEF1 is
bound to Groucho-related co-repressors, which recruit histone deacetylates (HDACs),
resulting in the repression of WNT target genes111,112. Stabilization and translocation of βcatenin into the nucleus displaces Groucho complexes when binding to TCF/LEF1113 and
the active complex recruits histone-modifying coactivators such as CBP/p300114,115.
TCF/LEFs functional roles are not just as activators, but some family members can
also act as repressors. For example, while TCF1 and LEF1 are more linked to WNT target
gene activation, TCF3 is generally known to be a WNT repressor 106,110. On the other hand,
TCF4 has been assigned either activating or repressor, depending on the isoform
expressed. For instance, different TCF4 spliced isoforms have been studied in
hepatocellular carcinoma cells. Those isoforms that contained an SxxSS motif were found
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to be growth suppressive, whereas those lacking the element were WNT activating and
growth promoting116,117.
Altered LEF1 expression and function commonly occur in several cancers 118. In
many cases, increased LEF1 expression results in poor prognosis in some solid cancers
including

colorectal

cancer 119,120,

oral

squamous

cell

carcinoma 121

and

lung

adenocarcinomas122. Given LEF1’s central role as a transcription factor in the WNT/βcatenin signaling pathway, it makes for a potential target therapeutic cancer treatment. To
illustrate, knockdown of LEF1 in colon cancer cells increased apoptosis in vitro and
reduced tumor growth formation in vivo compared to control cells123. In glioblastoma cell
lines, LEF1 knockdown inhibits invasion, migration, proliferation and self-renewal capacity
of stem-like cells124.

CURRENT COLORECTAL CANCER THERAPIES AND TREATMENTS
CRC is a very heterogeneous disease and evidence over the years points to the
fact that molecular and genetic features of a tumor can determine both the prognosis and
the response to targeted treatment. Usually patients with colon cancers up to stage II can
be treated by surgical resection only. Although the cancer might have grown through all
the layers of the intestine and into nearby organs, colon cancer cells have not spread to
neighboring lymph nodes. For stage II cancers, it is at the doctor’s discretion on whether
or not to provide chemotherapy treatments to the patient 125. Given the advances in primary
and adjuvant treatments, the median overall survival time in CRC has seen much
improvement. However, nearly 25% of patients with CRC present with metastases at the
time of diagnosis and another 25% will subsequently develop metastasis26,126,127.
Stage III colon cancers have spread to nearby lymph nodes, but they have not yet
spread to other parts of the body. Adjuvant therapy is standard for stage III tumors, where
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a combination of 5-fluorouracil plus oxaliplatin is used (where the mode of administration
will depend on the protocol followed)128. Most people with stage IV cancer will get
chemotherapies and/or targeted therapies to control the cancer. The goal of targeted
therapy is to attack the cancer cells without damaging the surrounding ‘normal’ cells, thus
leading to fewer side effects. Although each type of targeted therapy works a bit differently,
they all interfere with the ability of the cancer cell to grow, divide, repair and/or
communicate with other cells129. These therapies can include, but are not limited to,
monoclonal antibodies against EGFR (cetuximab and panitumumab) and monoclonal
antibodies against VEGF-A (bevacizumab)130, which targets angiogenesis.
Despite the overwhelming evidence that both loss of TGF-β and hyperactivation of
WNT pathway drive CRC, targeted therapies to the respective signaling pathways have
yet to make it to the clinic. Several inhibitors/drugs that block TGF-β signaling might
include small molecular inhibitors (SMI), neutralizing antibodies and others. Most current
TGF-β signaling inhibitors aim to directly inhibit either TGF-β receptor kinase activity or
TGF-β cytokine function131. Some drugs have received attention in the clinics. For
example, LY33022859 is an anti-TGFβRII monoclonal antibody that inhibits receptormediated TGF-β-signaling activation. Although tested in a subset of patients with
advanced solid tumors, it was determined that dose escalation for this drug was unsafe
due to negative symptoms132. Fresolimumab (GC1008), a human monoclonal antibody
neutralizing TGF-β-1/2/3, was tested in phase 1 with patients with malignant melanoma,
also resulting in many side effects and no significant clinical benefits 133. Generally
speaking, drugs targeting receptor kinase activity can lack absolute specificity and, at
certain doses, also target activin and nodal signaling pathways 131.
Theoretically, WNT-targeting approaches can be divided into three categories: 1)
targeting the WNT-ligand-receptor interface, 2) regulation of β-catenin destruction
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complex and 3) direct interference with β-catenin mediated transcription 134. Vantictumab
(OMP-18R5) is an antibody targeting Frizzled receptors135 and Ipafricept is a Frizzled
decoy receptor136. While both drugs have shown acceptable safety profiles for cancers
such as breast, ovarian and pancreatic, neither is currently under investigation in CRCs.
The reasoning behind, potentially, is that the majority of CRCs activate WNT signaling
independent of WNT ligand. Because β-catenin is the central effector of the WNT signaling
pathway, it seems the most reasonable approach to block WNT hyperactivation is by
inhibiting its transcriptional response. However, complete ablation of β-catenin can be
toxic to normal intestinal epithelium137. ICG-001 (PRI-724) is a small molecule that blocks
interaction of β-catenin with its co-activator CBP138. Although initially developed as a
potential treatment for multiple solid tumors, phase 1 trials for CRC indication are ongoing.
Although targeted therapies have been great in providing a better quality of life for
many CRC patients, it is also important to understand that they have certain limitations as
they only work in tumor subtype specific manner and are limited by the tumors mutational
profile. Understanding the functional role of CRC mutations is a pre-requisite for
development of combination therapies.

SUMMARY
The general introduction provided above serves as a base to understand the body
of work presented in this thesis. Although the consequence of loss of Smad4 (absence of
the protein) has been heavily studied, there is a gap in the literature in understanding a
molecular function (if any) for mutant Smad4 in colorectal cancer.
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CHAPTER 2: MATERIALS AND METHODS
Cell culture and treatments. Colorectal cancer cell lines SW480, SW620, and HCT116
3:6 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing
10% fetal bovine serum (FBS) and penicillin/streptomycin (p/s) at 37 °C and 5% CO2. For
the TGF-β treatment experiments, recombinant human TGF-β (R&D systems, 240-B-010)
was used at a concentration of 5 or 10ng/mL at the indicated time points. For the BMP2
or BMP4 treatment experiments, recombinant human BMP2 (R&D systems, 355-BM-010)
or BMP4 (R&D systems, 314-BP-010) was used at a concentration of 5 or 10ng/mL at the
indicated time points. Cells were treated with recombinant Wnt3a ligand (R&D systems,
5036-WN) at 100ng/mL at indicated time points.

Transient transfections and retrovirus-mediated gene transfer. For infection of CRC
cell lines with pMX-IRES constructs, retroviral particles were generated by transfection of
HEK 293GP cells with Lipofectamine 3000 (Invitrogen). The virus-containing medium was
collected after 8 hr or overnight and supplemented with 4 μg/ml polybrene (Sigma-Aldrich)
and 1% FBS. Subsequently, the virus was filtered using 0.45 µm filter and viral
supernatant was added to the target cells for 8 hours to overnight. Selection for infected
cells was done with 12.5 μg/ml Blasticidin (Gemini Bio Products) for over a week.

Plasmid generation. Plasmid encoding FLAG tagged, human Smad4 (Addgene item #
14039) was first subcloned into pBlueScriptII vector and subsequently cloned into pMXIRES-Blasticidin (Gemini Bio Products) retroviral vector. R361 Smad4 point mutations
were generated using Q5 Site-directed Mutagenesis kit (NEB Cat #E0554S) with primers
that carry the desired mutation. For LEF1 constructs, FLAG/MYC tagged LEF1 was
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purchased from Origene (CAT #RC208663). FLAG tag was substituted with an HA tag by
using Q5 Site-directed Mutagenesis kit (NEB) according to manufacturer’s protocol.

Chromatin Immunoprecipitation (ChiP) qPCR. SW480 cells (2.0 x 106) were fixed by
1% formaldehyde for 10 min at room temperature and were then quenched by 125 mM
glycine for 15 min at room temperature, washed with ice-cold PBS twice and centrifuged
at 200g, 4°C for 5 min. The pellet was resuspended in 1 mL of cell lysis buffer (10 mM
Tris-HCl, 10 mM NaCl, 0.5% NP-40, protease inhibitor) and kept at 4°C rotating for 30 min.
After centrifugation, the pellet was resuspended in 1 mL of nuclear lysis buffer (1% SDS,
10 mM EDTA, 50 mM Tris-HCl pH 8.0, protease inhibitor) and kept at 4°C for 60 min.
Lysate was then sonicated to an average size of chromatin fragments of 0.25–1.00 kb and
then frozen at -20ºC overnight. The chromatin was thawed on ice and centrifuged at
2,500g for 30 mins. Immunoprecipitation and DNA purification experiments were
performed using Chip-It High Sensitivity Kit (Active Motif # 53040) according to
manufacturer’s protocol. The immunoprecipitated fraction was analyzed by qRT-PCR to
determine the abundance of the target DNA sequence(s) relative to normal rabbit IgG
control.
Primer sequences (5’ to 3’) used:
Table 1. Primers sequences used for ChIP qPCR
Gene Locus

Forward primer

Reverse primer

PAI-1

GCAGGACATCCGGGAGAGA

CCAATAGCCTTGGCCTGAGA
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Luciferase assay. SW480, HCT116 3:6 and SW620 cells (200,000 per well) were seeded
into 12-well plates and rested overnight. Cells were then transiently transfected with
SBE4-Luc (Addgene #16495), pGL3-BRE-Luc (Addgene #45126), TOP-FLASH (Addgene
#12456) or FOP-FLASH (Addgene #12457) reporter plasmids for 24 hrs, using renilla
luciferase as internal control. For TGF-β, BMP and WNT treatments, transfected cells
were stimulated with TGF-β, BMP-2/4 or Wnt3a in serum-free media for an additional 24
hrs. Firefly luciferase reporter activity was measured with a dual luciferase reporter assay
kit (Promega), according to the manufacturer's protocol. Expression was calculated as the
ratio of firefly luciferase units normalized to renilla luciferase. These experiments were
independently repeated three times and each treatment consisted of triplicate samples.

Western blotting and antibodies. Whole cell protein lysates were prepared in RIPA
buffer (0.15M NaCl, l% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 1% Triton X100, 1mM phenylmethylsulfonyl fluoride, 0.05M Tris-HCl, pH 7.4) containing protease and
phosphatase inhibitors (Pierce Halt Inhibitor Cocktail, Thermo Scientific). Protein
concentrations were estimated by Biorad colorimetric assay (BCA). Bound antibodies
were detected with enhanced chemiluminescence (ECL kit, cat #) or by Odyssey Infrared
Imager (LI-COR Biosciences). The following primary antibodies were used: Smad4,
Smad2, Smad3, phospho-Smad2, phospho-Smad3, phospho-Smad1/5, BMPR2, Smad1,
Actin, HA (Cell signaling) and FLAG (Sigma-Aldrich). For secondary antibodies, goat antirabbit-HRP (GE Healthcare NA934V), goat anti-mouse HRP (GE Healthcare NA931V),
goat anti-mouse-680 (Licor 925-32220) donkey anti-rabbit-800 (Licor 926-32213) were
used. Dilutions were used according to the recommendation of the respective
manufacturers.
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CRISPR/Cas9 genome-editing system. Smad4 CRISPR/Cas9 knockout and homology
directed repair plasmids were purchased from Santa Cruz Biotechnologies (sc-400110
and sc-400110-HDR) and transfected into HCT116 3:6 cell lines through Lipofectamine
3000 (per manufacturer’s protocol). Effective Smad4 knockdown was confirmed by
western blotting.

Isolation of nuclear and cytoplasmic extract. The nuclear extraction was prepared
using an NE-PER Nuclear Cytoplasmic Extraction Reagent kit (Pierce, Rockford, IL, USA)
according to the manufacturer's instruction. Briefly, the treated cells were washed twice
with cold PBS and centrifuged at 500 g for 3 min. The cell pellet was suspended in 100 μl
of cytoplasmic extraction reagent I by vortexing. The suspension was incubated on ice for
10 min followed by the addition of 5.5 μl of a second cytoplasmic extraction reagent II,
vortexed for 5 s, incubated on ice for 1 min and centrifuged for 5 min at 16 000 g. The
supernatant fraction (cytoplasmic extract) was transferred to a pre-chilled tube. The
insoluble pellet fraction, which contains crude nuclei, was resuspended in 50 uL of nuclear
extraction reagent by vortexing during 15 s and incubated on ice for 10 min, then
centrifuged for 10 min at 16 000 g. The resulting supernatant, constituting the nuclear
extract, was used for the subsequent experiments.

Co-immunoprecipitation (co-IP). Cells stably expressing Flag-Smad4 (either wild-type
or mutated) were collected and subsequently lysed in lysis buffer (50 mM Tris–HCl at
pH 7.5 1M, 150 mM NaCl 5M, 1 mM EDTA, 1% Triton, 0.1% SDS, 0.5% NA-deoxycholate
plus protease and phosphatase inhibitors) and incubated with anti-FLAG M2 Affinity Gel
beads (Sigma-Aldrich) for 2 hrs at 4°C. The beads were washed 3 times with
immunoprecipitation (IP) buffer (150 mM, NaCl, 50 mM Tris, pH 8, 1% NP-40, 0.25%
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sodium deoxycholate) and bound proteins were eluted by boiling in nondenaturing sample
loading buffer and loaded onto PAGE gels. For detecting binding of LEF1 and Smad4,
expression constructs for LEF1-HA were transiently transfected into HCT116 3:6 cells
(stably expressing Smad4) for 48 hrs. Cells were then collected, lysed and
immunoprecipitation was performed as described above followed by detection through
western blot.

mRNA analysis. RNA was extracted using the RNeasy Kit (Qiagen) and TRIzol
(Invitrogen) and cDNA synthesis was performed using the Maxima First-Strand cDNA
Synthesis kit (ThermoFisher). Quantitative PCR analysis using SYBRGreen PCR Master
Mix (Thermofisher) was performed according to standard procedures.
Primer sequences (5’ to 3’) used:
Table 2. Primers sequences used for qPCR
Genes (all

Forward primer

Reverse primer

human)
PAI-1

ACAACCCCACAGGAACAGTC

GATGAAGGCGTCTTTCCCCA

SNAI2

CATGCCTGTCATACCACAAC

GGTGTCAGATGGAGGAGGG

PRSS8

CACCTTCTCCCGCTACATCC

AGGAGGCTCACTGAGGGG

NLRP2

GCAAAGGATGAAGTCAGAGAAGC

TTTTGAAGCGCTCCAGCATT

ACTIN

AGCATCCCCCAAAGTTCAC

AAGGGACTTCCTGTAACAACG

RNA-seq. Total RNA was extracted from SW480 cells using RNeasy Mini Kit (QIAGEN,
#74104) and polyA+ transcripts were isolated with NEB Next Poly(A) mRNA Magnetic
Isolation Module (NEB, #7490). RNA-Seq libraries were prepared with NEBNext Ultra II
Directional RNA Library Prep Kit for Illumina (NEB, E7760S). Three biological replicates
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were sequenced on a NextSeq 500 (Illumina) at a depth of at least 2x10 7 reads each.
Reads were mapped and analyzed with a bioinformatic pipeline based on GSNAP,
featureCounts, and the R packages limma and edgeR. We used human genome version
GRCh38. GO analyses were performed using version 6.8 of the DAVID web server. GSEA
analyses were performed using pre-ranked GSEA using a weighted scoring.

Statistics and reproducibility. All statistical analyses were carried out using Graph Pad
Prism (version 7) by unpaired student’s t-test for two group comparisons, Yate’s continuity
corrected chi-square test for contingency table analysis, and Gehan-Breslow-Wilcoxon
test for survival curves. Error bars represent s.e.m. ± SD and statistical significance were
defined as P < 0.05.
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CHAPTER 3: SMAD4 WITH R361 HOTSPOT MUTATIONS RETAINS THE

ABILITY TO BIND TO LEF1 AND BOOSTS WNT SIGNALING IN
COLORECTAL CANCER

INTRODUCTION
In normal and premalignant cells, TGF-β can exert tumor-suppressive effects by
inhibiting cell proliferation, stimulating differentiation and inducing apoptosis139. However,
tumor cells can evade TGF-β tumor suppression through inactivation of either the
receptors or downstream effectors, which disables the entire signaling cascade. For
example, TGF-β RII is frequently mutated in colon carcinoma cells from patients with
microsatellite unstable (MSI) CRC, a phenomenon defined by faulty DNA mismatched
repair machinery5. Inactivating mutations in Smads, specifically Smad4, have been found
in various types of cancers such as lung and pancreatic carcinomas83,87,140–142 and germline mutations are common in juvenile polyposis, a disease which predisposes individuals
to gastrointestinal malignancies86. Smad4 alterations are also found in 10-35% of CRC
tumors and tend to appear late in the adenoma-to-carcinoma progression143,144. Complete
loss of Smad4 in colorectal cancer patients can be due to deep deletions or frameshift
mutations. We and other have shown that it is frequently associated with increased
angiogenesis81,145, lymph node metastasis, advanced disease, and poor prognosis84. In
addition, many patients acquire missense mutations, which cluster in the MH2 domain of
the protein. While mutations in the MH2 domain mainly affect residues close to protein
interface involved in hetero-oligomerization of Smad4 with R-Smads which is required for
transcriptional activation53,55, mutations in the MH1 domain have been shown to alter
protein stability and binding to the DNA49,146. Thus, Smad4 missense mutations are
thought to be loss-of-function. However, there is a considerable gap in our understanding
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of their role in CRC progression and whether these mutant forms of Smad4 retain or
acquire any functions.
In this results section, we report that R361 Smad4 variants can function
independently from TGF-β-signaling and positively regulate WNT signaling, a pathway
often hyperactivated in CRC16. We demonstrate that mutant Smad4 binds to lymphoid
enhancer binding factor-1 (LEF1) protein and facilitates transcriptional activation of WNT
signaling in CRC cells. Overall, we establish a novel function for mutant Smad4 proteins
in the progression of colorectal cancer.

RESULTS
SMAD4 is frequently mutated in colorectal cancer
To understand the clinical relevance of SMAD4 mutations in CRC, we analyzed
SMAD4 mutation data in recent Memorial Sloan Kettering Cancer Center (MSKCC) study,
which generated cancer gene panel data from 1,134 colorectal adenocarcinomas from
patients with both metastatic and early-stage CRC. While all the TGF-β signaling
components exhibit some genetic alteration, SMAD4 was the most frequently altered gene
from the TGF-β signaling pathway (Figure 5A)21. Of all SMAD4 mutations and copy
number alterations, missense mutations classified as putative drivers were the most
abundant. Although they could be found across the MH2 domain, we confined subsequent
analyses to amino acid substitutions in the R361 residue, as they were found at a much
higher frequency than other missense mutations in this data set and other CRC
studies143,147 (Figure 5B).
To study R361 mutations in CRC cells, we generated retroviral constructs
expressing either Smad4 wildtype (WT) or point mutations at the MH2 domain of Smad4,
specifically at the arginine 361 residue (R361) and bearing FLAG tag at the N-terminus.
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We transduced those constructs into cells lines that lack detectable endogenous Smad4
protein, SW480 and SW62088, but have otherwise intact TGF-β signaling pathway
components148 (Figure 6A). After transduction with the retroviral constructs, we were able
to detect robust protein expression by Western blotting using the α-Smad4 antibody
(Figure 6B). To study the Smad4 mutations in additional TGFβ-responsive cell lines, we
used an HCT116 engineered derivative HCT116 3:6, which have intact TGF-β
signaling149. To render them Smad4-deficient, we used Santa Cruz CRISPR-Cas9
knockout (KO) and homology directed repair (HDR) plasmid according to manufacturer’s
protocol. Edited HCT116 3:6 cells were cloned using flow cytometry and a single cell clone
with no trace of Smad4 expression was identified using Western blotting (Figure 6C & 6D).
When comparing the level of expression between parental HCT116 3:6 cells (which
express endogenous Smad4 protein) and our retroviral constructs, we observe that
HCT116 3:6 cell lines transduced with Smad4-retroviral constructs express ~2-3X as
much Smad4 protein as those with endogenous Smad4 (Figure 6E). Thus, although levels
of retrovirally expressed Smad4 didn’t exactly match those seen in CRC, they were not
grossly elevated either. Finally, the effects of R361-mutation on the turnover of Smad4
was examined in SW480 cells using cycloheximide treatment (25ug/mL for 0, 6 and 12
hrs). It was observed that both Smad4-WT and Smad4-R361H/C protein start degrading
between 6-12 hrs (Figure 6F), suggesting that mutations at the R361 residue did not affect
the half-life of Smad4 protein.
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A

B

Figure 5. Smad4 is frequently mutated in CRC. (A) MH2 hotspot mutations of SMAD4
are marked on the lollipop plot downloaded from the MSKCC (2018) study on cBioportal.
(B) The prevalence and spectrum of SMAD4 mutations in MSKCC study.
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Figure 6. Generation of Smad4 CRC mutant cell lines. (A) Western blot analysis of
cells lacking endogenous expression of Smad4, using HCT116 3:6 as positive control. (B)
Western blotting confirming retroviral expression of Smad4 in SW480 and SW620 cell
lines. (C) Western blot comparing levels of Smad4 protein in A549, HEK293, HCT116 3:6
and HCT116 3:6 Smad4 KO cell lines. Actin was used as loading control. (D) Western
blotting confirming retroviral expression of Smad4 in HCT116 3:6 cells. (E) Western blot
comparing the levels of endogenous versus retroviral transduced Smad4 protein. Actin
was used as a loading control. (F) Determination of Smad4 half-life. SW480 cells were
treated with 25ug/mL of cycloheximide for either 0, 6 or 12 hrs, followed by western blot
with the indicated antibodies. p21 was used as a positive control and actin was used as a
loading control.
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SMAD4 R361 missense mutations prevalent in colorectal cancer result in loss of
binding to phosphor-Smad2/3
Because Smad4 is an important factor in TGF-β signaling, we asked whether there
were major differences in TGF-β upstream signaling pathway. Stimulation of these two
cell lines for 1 hour with 5ng/mL of TGF-β resulted in phosphorylation of receptor regulated
Smads (i.e., Smad2 and Smad3, Figure 7A) regardless of Smad4 status. This was
expected since phosphorylation of Smad2/3 is an initial step in the TGF-β signaling
cascade and upstream of Smad4 signaling. However, R361 is in the loop helix region of
the Smad4 MH2 domain and is an important residue in forming a Smad4 heterocomplex
with R-Smad38. To test whether mutations at the R361 residue are still able to bind to
phosphorylated Smad2 and Smad3, we performed immunoprecipitation analysis on
SW480 cells treated with either vehicle control or soluble TGF-β. While wild-type Smad4
was able to bind to both R-Smads, both mutations R361H and R361C abolished
interaction with R-Smads in CRC cells (Figure 7B). This suggests that this missense
mutation affects heterodimerization between Smad4 and Smad2/3 but does not affect
overall phosphorylation of Smad2/3.
In a basal state, Smad4 is distributed throughout the cell and may undergo
continuous shuttling between the cytoplasm and nucleus – presumably due to the
combination of an active nuclear localization signal (NLS) in its MH1 domain and its
nuclear export signal (NES) in its linker region. During active TGF-β signaling, binding of
R-Smads to Smad4 is thought to mask the NES in Smad4, thus allowing the complex to
accumulate in the nucleus49. Because R361 mutations are unable to associate with RSmads, we decided to investigate whether or not Smad4 mutations can concentrate into
the nucleus following TGF-β treatment. Following treatment with soluble TGF-β ligand,
only wild-type Smad4 was able to accumulate in the nucleus while Smad4-R361H and
Smad4-R361C mutants could not. (Fig. 7C, 7D quantification). These results suggest that
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Smad4-R361 mutations are unable to bind to R-Smads and cannot concentrate in the
nucleus in the presence of active TGF-β signaling.
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Figure 7. Smad4-R361 mutations cannot bind p-Smad2/3 in CRC cells in response
to TGFβ. (A) SW480 and SW620 cell lines treated with either vehicle control or 5ng/mL
for an hour. Western blotting was performed to detect phosphorylation of Smad2 and
Smad3, and total levels of Smad2 and Smad3 as indicated. Actin was used as loading
control. (B) SW480 cells were treated at 0' or 60' with soluble TGF-β followed by
immunoprecipitation with FLAG conjugated beads. Input/Whole Cell Lysate (WCL) was
used as a control. (C) SW480 cells were treated at 0' or 60' with soluble TGFβ followed
by a nuclear cytoplasmic fractionation. Lamin A/C was used as nuclear marker and alpha
tubulin was used as cytoplasmic marker. (D) Quantification of nuclear Smad4 in SW480
experiment.
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Smad4 mutants do not support canonical TGF-β-induced transcriptional activity
Activated Smad complexes accumulate in the nucleus, where they can bind
directly or indirectly to DNA and regulate gene expression. Because Smad4 is a critical
effector of TGF-β signaling, we tested whether R361 mutations in Smad4 have altered
transcriptional activity. Smad4 wild-type and Smad4 mutant stably expressing cells lines
were transiently transfected with a luciferase vector containing 4 copies of the Smad
binding element (SBE), a sequence that allows for Smad-DNA binding43. As expected,
Smad4-WT was able to support downstream TGF-β transcriptional activity in the presence
of soluble TGF-β in all three of our CRC cells lines (SW480, SW620 and HCT116 3:6).
However, both Smad4-R361 mutations were unable to support canonical TGF-β
transcriptional activity and behaved similarly to the empty-vector cells (Figure 8A). There
has been uncertainty as to whether mutations in Smad4 could exert a dominant-negative
effect over Smad4-WT62,89. We therefore tested the ability of mutant Smad4 to interfere
with Smad4- mediated TGF-β responsive transcription. Due to ease of transfection, we
used the HCT116 3:6 Smad4 knockout (KO) clone cell line to test whether or not mutant
Smad4 acted in a dominant negative manner over wild-type Smad4. Transfection of
increasing amounts of either Smad4-R361H or -R361C had no effect on induction of SBE
reporter gene by TGF-β (Figure 8B) arguing against the dominant negative mechanism.
To further confirm the decrease in transcriptional activity of Smad4-R361 mutants, we
performed quantitative analysis of Smad4-targeted gene expression by real-time
quantitative RT-PCR (qRT-PCR). The expression of PAI-1 and SNAI2, both well-validated
direct Smad4 target genes, was compared in SW480 cells expressing different Smad4
constructs and the empty vector. Consistent with the reporter assay, in TGF-β-treated
SW480 cells, only Smad4-WT was able to induce the expression of these Smad4 target
genes by more than 2-fold, whereas this induction was not seen in cells overexpressing
Smad4- R361 mutations (Figure 8C).
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Smad4 binds directly to the promoter region of PAI-1150. To provide further
evidence that mutant Smad4 is unable to regulate PAI-1 gene expression in the presence
of TGF-β, we performed chromatin immunoprecipitation (ChIP) assay followed by qRTPCR. As expected, stimulation of cells with TGF-β induced the recruitment of Smad4-WT,
but not Smad4-R361 mutant protein to the promoter region of PAI-1 (Figure 8D). Taken
together, these data indicated that Smad4-R361 mutations completely disengage from the
TGF-β pathway and neither activate nor repress canonical TGF-β signaling, even when
overexpressed.
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Figure 8. Stably expressed Smad4 mutants do not support canonical TGFβ-induced
transcriptional activity. (A) SW480, SW620 and HCT116 3:6 cells transfected with the
SBE-Luciferase construct, later treated with either vehicle control or soluble TGFβ ligand.
pRL-TK plasmid was used as an internal control. (B) HCT116 3:6 cells were transiently
transfected SBE-Luciferase construct, with either a 1:1 or a 1:3 ratio of Smad4WT:Smad4-R361 mutant plasmid for 24 hours, followed by treatment with either vehicle
control or soluble TGFβ for another 24 hours. Cells were then lysed, and luciferase activity
in lysates was determined. Renilla plasmid was used as an internal control. (C) Induction
of PAI-1 and SNAI2, TGFβ target genes, were measured after TGFβ treatment by qRTPCR in SW480 cells. Actin was used as internal control. (D) SW480 cells were plated and
treated with 10ng/mL of soluble TGFβ for an hour. Chromatin fraction was prepared from
harvested cells to analyze binding of Smad4 to indicated promoter using ChIP-qPCR with
anti-Smad4 or anti-IgG.
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Smad4 mutants do not support canonical BMP-induced transcriptional activity
Although our studies so far have mainly focused on the TGF-β signaling pathway,
it is important to reiterate that Smad4 can mediate gene responses in a variety of other
pathways. One of the other well studied TGF-β signaling pathways is that of Bone
Morphogenic Protein (BMP). BMP ligands also bind to type II and type I serine-threonine
kinase receptors and mediate their signaling through both Smad and non-Smad signaling
pathways. As mentioned in Chapter 1 of this thesis: of the eight Smad proteins identified
in mammals Smad1, Smad5 and Smad8 are the R-Smads activated by BMP type I
receptors151. While BMPs can be divided into several subgroups, BMP-2/4 group has
been most recently identified to play a role in colorectal cancer 152.
Due to the fact Smad4 (co-Smad) is shared by both BMP and TGF-β signaling
pathways, we also wanted to understand whether or not mutations in Smad4 affects BMP
signaling. Because phosphorylation of R-Smads is the initial step in activation, we decided
to look at the effect of BMP upstream signaling pathway. Stimulation of SW480 for 1 hour
with 50ng/mL of either BMP2 or BMP4 resulted in phosphorylation of receptor regulated
Smad1/5 in cell lines expressing wild-type Smad4. Interestingly, we see that cells
containing no Smad4 or Smad4-R361 mutation have reduced phosphorylation of RSmads (Fig 9A), an event that we did not see when we treated cells with TGF-β and
analyzed phosphorylation of Smad2/3 (Fig 7A). This event, however, would need to be
confirmed in the other CRC cell lines used in our study.
Similarly, in our SBE-luciferase assays, Smad4-WT was able to support
downstream BMP transcriptional activity in the presence of soluble BMP2 and BMP4 in
SW480 and HCT116 3:6 cell lines. However, both Smad4-R361 mutations were unable to
support canonical BMP transcriptional activity and behaved similarly to the empty-vector
cells (Fig 9B). Finally, to test whether Smad4-R361H is still able to p-Smad1/5, we
performed immunoprecipitation analysis on SW480 cells treated with either vehicle control
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or soluble BMP2 and BMP4. Similar to our p-Smad2/3 assay, only wild-type Smad4 was
able to bind to p-Smad1/5 as Smad4-R361H completely abolished that interaction (Fig
9C). Overall, mutating R361 residue affects heterodimerization of Smad1/5 and
downstream BMP signaling.
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Figure 9. Smad4-361 mutations result in loss of downstream BMP signaling (A)
SW480 cell lines treated with either vehicle control or 50ng/mL of BMP2 or BMP4 ligand
for an hour. Western blotting was performed to detect phosphorylation of Smad1/5, and
total levels of Smad1 and BMPR2 as indicated. Actin was used as loading control. (B)
SW480 and HCT116 3:6 cells transfected with the BRE-Luciferase construct, later treated
with either vehicle control or 50ng/mL of BMP2 or BMP4 ligand. pRL-TK plasmid was used
as an internal control. (C) SW480 empty, Smad4-WT and R361H expressing cells were
treated with either vehicle, BMP2 or BMP4 ligand followed by immunoprecipitation with
FLAG conjugated beads. Input/Whole Cell Lysate (WCL) was used as a control.
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R361H confers the gene signature associated with LEF1 protein overexpression.
Although with respect to canonical TGF-β targets Smad4-R361 mutations appear
to be loss-of-function, we reasoned that a hotspot mutation is more consistent with a gainof-function mechanism. To uncover such a mechanism, we performed RNA-Seq analysis
on SMAD4-transduced SW480 cells treated with soluble TGF-β for 24 hr (Figure 10A).
Principal component analysis (PCA) performed on all expression datasets revealed that
as expected, Smad4-WT is the only group strongly affected by the treatment with soluble
TGF-β (Figure 10B). However, unexpectedly, the SMAD4 mutant samples separated very
strongly from the SMAD4-null samples, with or without TGF-β treatment. This separation
was the first experimental evidence of nonequivalence of SMAD4-null and missense
mutations. To understand the specific differences between CRC cells expressing no
Smad4 and Smad4-R361 mutations, we further analyzed our RNA-Seq data set by gene
set enrichment analysis (GSEA). We discovered that Smad4 R361H-associated genes
are most significantly enriched in the members of the following datasets: genes down or
up-regulated in DLD1 cells (colon carcinoma) over-expressing LEF1 (Figure 10C). This
enrichment was strongly driven by the cluster of genes that were expressed at high levels
in SMAD4-null cell but downregulated in SMAD4-WT and especially in SMAD4-MUT cells
(Figure 10D) such as known colon cancer metastasis suppressor PRSS8 153, putative CRC
tumor suppressor RAB25154, and an NF-kB inhibitor NLRP2155. To confirm that a
transcriptome associated with LEF1-levels was indeed affected, we reproduced RNA-seq
results by analyzing single genes by qRT-PCR. Indeed, we saw that transcription of genes
included in the list: NLRP2 and PRSS8 showed downregulation in cells containing both
Smad4 R361H and R361C mutant compared to cells expressing no Smad4. Of note,
RAB25 was significantly downregulated in cells expressing Smad4-R361C, but not
Smad4-R61H, when compared to empty vector cells (Figure 10E).
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The RNA-seq data showed that LEF1-associated gene signature is affected in
cells expressing Smad4 mutant vs empty vector cells. To study this effect at the molecular
level, we first determined that the level of LEF1 protein was unchanged between empty
vector, Smad4-WT and Smad4-R361 CRC cells (Figure 11A). Previous studies have
demonstrated that Smad4 WT and LEF1 can bind each other in neuroblastoma and
fibroblast-like cells156,157. To investigate whether or not Smad4-R361 mutants can bind
LEF1 protein in CRC cells, we transiently transfected Smad4-transduced HCT116 3:6
cultures with an HA-tagged LEF1 construct followed by immunoprecipitation. We observed
that both Smad4-WT and Smad4 R361H/C can bind LEF1 protein in CRC cells (Figure
11B), but the consequences of this interaction remained to be determined.
It’s been previously shown amino acids 511-552 are crucial for interaction of
SMAD4 with LEF1157. However, when we tried to generate a Smad4Δ510-552 construct,
we are unable achieve Smad4 protein expression as examined through western blot
analysis (data not shown). To determine the domain essential for Smad4-LEF1 interaction,
we generated two Smad4 deletion constructs: Smad4Δ535-552 and Smad4Δ543-535
(Figure 11C). We first transfected these constructs into HEK cells to validate their
expression (Figure 11D) via western blot, and then tested whether or not they could retain
binding to LEF1. Again, we transiently transfected Smad4-transduced HCT116 3:6
cultures with an HA-tagged LEF1 construct followed by immunoprecipitation. We observed
that while Smad4-WT can bind to LEF1 protein, that binding is significantly reduced in
both

Smad4Δ535-552

and

Smad4Δ543-535

samples

(Figure

11E

and

11F,

quantification). This led us to believe that Smad4 amino acids 535-552 might be essential
for binding to LEF1.
As LEF1 is a key downstream effector of the WNT pathway, we evaluated WNT
signaling status in our CRC cell lines. Specifically, we employed the TOP-Flash/FOPFlash luciferase reporter that contains 7 copies of TCF/LEF binding sites. When incubated
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in basal media, R361 Smad4 mutants were able to induce downstream WNT signaling at
higher levels compared to no-Smad4 and wild-type Smad4 in both SW480 and HCT116
3:6 cells (Figure 12A). Since SW480 are not responsive to Wnt3a (data not shown), we
continued our studies with HCT116 3:6 cells. When HCT116 3:6 Smad4 cells were treated
with soluble Wnt3a ligand, we observe an increase in WNT signaling compared to vehicle
control. In addition, there was significant up-regulation of WNT signaling by R361 mutants
when compared to cells expressing no Smad4 and wild-type Smad4 (Figure 12B). We
conclude that these two Smad4 mutations, which are associated with the loss of TGF-β
response in human cancer cells, still retain a TGF-β-independent function of Smad4,
activation of downstream WNT signaling.
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Figure 10. R361H has the gene signature associated with upregulation of TCF/LEF1
protein complex. (A) Schematic representation of our RNA-Seq workflow. (B) Principal
component analysis (PCA) for different treatment groups as indicated. (C) GSEA summary
of pathways associated with genes differentially regulated in cells expressing Smad4R361H vs empty vector expressing cells. (D) Heat map representing the gene expression
in CRC cells expressing Smad4-R361H mutant, Smad4- WT and empty vector (E) qRTPCR validation on NLRP2, PRSS8 and RAB25 transcript on SW480 cells. Actin was used
as endogenous control and empty vector cells were used to normalize expression of all
three genes.
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Figure 11. Smad4-binds to LEF1. (A) Western blotting showing the levels of Lef1 protein
in SW480 cell lines. (B) HCT116 3:6 cells were transfected with Lef1-HA constructs for 48
hours followed by immunoprecipitation with FLAG-conjugated beads. Input/Whole Cell
Lysate (WCL) was used as a control. Asterisks represent unspecific band in the empty
vector lane, likely due to antibody background. Immunoprecipitation was repeated three
times with the same results. (C) Diagram of Smad4 mutation constructs generated to test
which domains are necessary to bind to LEF1. (D) HEK cells were transiently transfected
with Smad4-WT, ∆Smad4 535-552 and ∆Smad4 543-552 to confirm expression of protein.
Actin was used as loading control. (E) IP and western blot assays showing the interaction
between Smad4 and LEF1 in HCT116 3:5 cells transfected with different FLAG-tagged
Smad4 deletion constructs and HA-tagged LEF1 construct. Asterisks represent unspecific
band in the empty vector lane, likely due to antibody background. (F) Quantification of
blots from panel E.
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WNT activation and SMAD4 missense mutations in primary CRCs
We then asked whether there is an epistatic relationship between Smad4
missense mutations and WNT activation in CRC patients. To answer this question, we reanalyzed the MSKCC cancer panel study. In microsatellite stable CRC samples, SMAD4
has a 15% frequency of mutation while CTNNB1 (β-catenin) has a lower mutation
frequency of 4% (Figure 12C), likely due to APC already being mutated in many CRC
patients14. We reasoned that if SMAD4 missense mutations aid WNT signaling, activating
missense mutation in CTNNB1 will be under even less selective pressure to occur. This
would be in contrast to SMAD4 truncating mutations, which do not affect WNT signaling.
To compare and contrast the co-occurrence frequency of CTNNB1 mutations in CRCs
alongside either SMAD4 missense or loss-of-function nonsense mutations89,158, we
utilized the chi-square test with Yate’s correction. Indeed, we observed highly statistically
significant enrichment for CTNNB1 mutations in CRC with nonsense mutations, at the
expense of tumors with SMAD4 missense mutations (Figure 12D).
Finally, to understand the contribution of R361-mutations to clinical outcomes in
CRC patients, we analyzed median overall survival (OS) in the MSKCC cohort. When
compared with patients with no SMAD4 alterations, patients with SMAD4 missense
mutations had a shorter OS survival of 70.03 vs 40.5 months (p = 0.0186). This difference
was not be observed in patients that had no alteration for SMAD4 versus patients with
SMAD4 truncating nonsense mutations (OS survival of 70.03 vs 68.3 months respectively,
p = 0.9076) (Figure 12E, left and right). These data demonstrate that CRC patients with
SMAD4 missense mutations do worse overall than those with unaltered SMAD4 and
truncating mutations in SMAD4, attesting to their gain-of-function properties.
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Figure 12. Smad4 R361 mutants boost Wnt signaling. (A) SW480 and HCT116 3:6
cells were transfected with either a TOP-flash or FOP-flash construct and collected after
48hrs. pRL-TK plasmid was used as an internal control. (B) HCT116 3:6 cells were
transfected with either a TOP-flash or FOP-flash construct, later treated with either vehicle
control or Wnt3a ligand. pRL-TK plasmid was used as an internal control. (C) Oncoprint
of SMAD4 and CTNNB1 mutations of MSS CRC patient samples, which were then
analyzed using the cBio Portal for Cancer Genomics platform. (D) CRC patients with
SMAD4 missense mutations containing CTNNB1 missense mutations (3) or CTNNB1
wild-type (123) or SMAD4 truncating mutations containing CTNNB1 missense mutations
(6) or CTNNB1 wild-type (48). Statistical significance using Yate’s continuity corrected chisquare test: p = 0.00367. (E) Comparison of survival curves in patients with no SMAD4
alterations and SMAD4 missense mutations (left) and no SMAD4 alterations and SMAD4
truncating mutations (right). Statistical significance per log-rank (Mantel-Cox) test: p =
0.0186 and p = 0.9076 respectively.
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DISCUSSION
Defects in Smad4 play a significant role in the malignant progression of tumors
and are frequently altered in colon and pancreatic carcinomas 21,83. About 10-30% of CRC
patients harbor some loss of Smad4, either by deep deletion or nonsense mutations.
Interestingly, missense mutations in Smad4 also have been identified in variety of cancers
including CRC. In these tumors, Smad4 mutations appear frequently at the MH2 domain.
By analyzing both primary tumors and immortalized cells lines, two of the most frequent
Smad4 missense mutations have been identified at position 361 which results in a
substitution from arginine to either histidine or cysteine 55. These genetic hits are
recurrently detected in Smad4, consistent with the idea that this gene acts as a tumor
suppressor. On the other hand, their clustering in distinct hot spots argues that Smad4
mutants, similar to mutant have an oncogenic function; however, this hypothesis has not
been previously tested.
In the present study, we investigated the functional roles of the missense mutations
R361H and R361C in the Smad4 MH2 domain that naturally occur in human colorectal
cancer patients55. This was achieved by the means of retroviral transduction into cell lines
that lack endogenous Smad4 protein. Smad4 missense mutations had been previously
mapped onto the crystal structures of Smad heterodimers, specifically onto the defined
protein loop that is directly involved in binding to the R-Smads. Our coimmunoprecipitation experiments indicate that point mutations in Smad4 MH2 domain
indeed disrupt binding to endogenous p-Smad2, p-Smad3 and p-Smad1/5. We also
showed in transfection assays that Smad4 missense mutations cannot support
transcription from reporters driven by Smad3–Smad4 (CAGA12- luciferase) complexes.
In addition, Smad4-R361 mutations could also not support downstream BMP signaling
when we used a BMP-specific reporter. Although it seems that these mutations also
cannot activate downstream BMP signaling, more experiments would be needed to solidify
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this claim. For example, apart from looking at BMP-signaling using a reporter assay, we
could confirm loss of canonical BMP target genes such as Id1 and Id2153,154 via qRT-PCR.
In addition, we could also determine if Smad4 can bind to the promoter of BMP target
genes through Chromatin Immunoprecipitation (ChiP) as we did with TGF-β/SMAD4
target, PAI-1.
Admittedly, some tumor suppressor genes can have dominant negative effects.
For example, mutant p53 protein can bind to its wild type counterpart encoded by the
unaltered allele and sequester it in non-functional complexes159. However, when we coexpressed mutant and wild- type Smad4, we observed no dominant negative effects of
the former. Taken at face value, these experiments would suggest that Smad4 variants
are loss-of-function. This mechanism is supported by several lines of genetic evidence,
including a frequent loss of heterozygosity (LOH) at chromosome locus 18q where SMAD4
is located; such loss is associated with a poor prognosis for CRC patients 160,161. Yet the
very high prevalence of R361 SMAD4 mutations in CRC patients, particularly in those with
distant metastasis vs. locally advanced tumor 93

indicated that additional molecular

mechanisms could be at play.
The idea that Smad4 can lose canonical TGF-β functionally but maintains some
TGF-β-independent function had been proposed before. For example, it was suggested
previously that Smad4 cooperated with LEF1 to increase c-myc expression in the absence
of TGF-β signaling162; however, that study did not investigate the effect of this interaction
on WNT signaling. Furthermore, to our knowledge, the ability of mutant Smad4 to bind to
LEF1 and the consequence of that binding has not been previously studied. Here, we
propose that Smad4-R361-mutant loses its tumor suppressive arm and retains binding to
LEF1, resulting in enhanced WNT signaling. We do not know for the fact why there is more
WNT signaling in Smad4-R361 CRC expressing cells compared to those expressing
Smad4-WT. It is possible that the inability of Smad4 R361 mutant to bind R-Smads
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following TGF-β stimulation increases the pool of available protein to bind to LEF1;
however, more experimentation will be required to test this hypothesis. In addition, it is
possible that this LEF1-Smad-R361complex does not act alone, and could include other
transcription factors, such as β-catenin, to assist in downstream activation of WNT
signaling. However, β-catenin binding has been understudied and independent
publications yielded mixed results163–165.
The four CMS subtypes differ in genetic and epigenetics, as well as the signaling
pathways they follow. While CMS1 is characteristic of tumors with MSI, tumors with CIN
can be subclassified on the basis of gene expression: CMS2 (canonical subtype), CMS3
(metabolic subtype) and CMS4 (mesenchymal subtype)31. Copy number variation in both
oncogenes and tumor suppressor genes are found more frequently in CMS2 than in other
subtypes and they display a strong upregulation of WNT and MYC downstream targets.
Interestingly, SMAD4 mutations were profiled across different molecular subtypes and
found to be most common with the CMS3 subtype143, however, that classification was not
specific to SMAD4 missense mutations. Based on our data and overall working model, we
would expect that SMAD4 missense mutation (especially hotspot mutation R361) to be
commonly found in the CMS2 subtype due to their marked upregulation of WNT pathway.
However, this hypothesis could not be tested directly using our dataset due to the lack of
RNA-Seq data in the MSKCC cohort. Nevertheless, based on our survival data, the
interaction between Smad4-R361 and LEF/TCF protein complexes may be a good
therapeutic target.
Our work raises additional questions that will be addressed in future studies. TGFβ not only induces Smad-mediated responses, but also activate Smad-independent
responses, which allow additional versatility and diversification of TGF-β family responses.
The non-Smad pathways include, but are not limited to, the activation of other mediators
such as those involved in MAPK kinase pathways39. Loss of Smad4 has been shown to
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induce tumorigenicity and 5-FU (5-fluoracil) resistance through activation of the Akt
pathway, which results in upregulation of anti-apoptotic proteins166. Another study
revealed that patients with advanced disease observed a markedly shorter progressionfree survival time in patients with SMAD4-mutated tumors than in those wild-type for
SMAD4, when treated with anti- epidermal growth factor receptor (EGFR) treatment143.
This suggests that mutant Smad4 might be playing a role that affects signaling pathway,
possibly via binding to other, yet to be identified transcription factors.
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CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS
OVERVIEW
As we summarize our findings and conclude our discussion, we end with an
examination on future directions of this thesis project. We provide proposals for future
experiments that will validate our findings, make suggestions of various avenues to pursue
that could provide valuable insight, and outline how breakthroughs on defining this
pathway further can open up possibilities to create better therapies for CRC cancer
patients.

LIMITATIONS OF COMPLETED WORK & FUTURE DIRECTIONS
Elucidating molecular mechanism by which Smad4 R361 regulates WNT
signaling
Here we proposed that Smad4-R361-mutant loses its tumor suppressive arm and
retains binding to LEF1, resulting in enhanced WNT signaling. Although we have
described this event in detail in this thesis, we still do not know exactly how this is
occurring.
Firstly, we can speculate that the inability of Smad4mut to bind to Smad2/3
following TGF-β treatment increases the pool of available mutSmad4 to bind to LEF1. This
would redirect Smad4mut to upregulate WNT signaling, while Smad4 wild-type regulates
TGF-β and WNT signaling simultaneously. A possible way that we could test this
hypothesis is to determine the effect of TGF-β signaling on WNT signaling in CRC cell
lines. To test this, we could perform the TOP/FOP assay on the HCT116 3:6 cells and
treat the cells with either the TGF-β soluble ligand or a TGFβ receptor kinase
(ALK5/TGFβRI) inhibitor SB431542167. If our redirection hypothesis is true, we would
expect that blocking TGF-β signaling would increase WNT signaling in our CRC cells
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expressing both mutant and wild-type Smad4. However, there is a possibility that inhibition
of TGF-β signaling will reduce WNT signaling, suggesting that the two pathways are
working together. If this is our result, a way to possibly explain this would be through
inhibitor Smad, Smad7, which is a downstream target gene of TGF-β signaling. In the
cytoplasm, Smad7 is one of the points that link the two pathways. It is well known that
Smad7 functions to compete with Smad2/3 for receptors, which leads to ubiquitination and
degradation of receptors and hence inhibiting Smad2/3 phosphorylation and activation 38.
However, Smad7 has been found to disassemble the β-catenin destruction complex by
binding to AXIN, thus stabilizing β-catenin and promoting its nuclear translocation 168.
When we treat parental HCT116 3:6 cells with TGF-β ligand, we have seen an
upregulation of SMAD7 transcript (data not shown). Given that Smad7 is upregulated in
the presence of TGF-β signaling, and Smad7 has been shown to regulate WNT signaling;
it would make sense that inhibiting TGF-β could also result in downregulation of WNT
signaling.
In addition, a recent study by Voorneveld et al claims that BMP can affect WNT
signaling depending on both SMAD4 and p53 status. In the normal colonic epithelium, the
BMP pathway counteracts WNT signaling pathway in order to maintain tissue
homeostasis169. In their study, they found that wild-type p53 is necessary for BMP to
inhibit WNT signaling and loss of Smad4 completely reverses the BMP-WNT interaction,
switching from inhibition to activation164. This is the opposite of what we see in CRC cells,
as presence of Smad4 wild-type protein actually enhances WNT signaling compared to
empty vector cells (expressing wild-type p53). Nevertheless, it would be interesting to
explore a BMP-SMAD4-WNT axis to help us better understand the effects of Smad4
mutations on WNT signaling. If somehow BMP signaling is redirecting Smad4 to enhance
WNT signaling, we could test this theory by using a similar experimental setup as
proposed above. We would use our CRC cell lines and either treat with BMP ligand or
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inhibit BMP signaling using an inhibitor (LDN-193189)170, followed by a TOP/FOP
luciferase assay to measure downstream WNT signaling. In general, understanding the
molecular mechanisms of how Smad4mut is able to upregulate WNT signaling compared
to wild-type Smad4 in colorectal cancer cells would further validate our findings stated in
this body of work.

Uncovering Smad4 mutant phenotype in vitro and in vivo
Here, we presented evidence that mut-Smad4 is unable to promote canonical
downstream TGF-β signaling (Figures 7 & 8). Although the work done in this thesis sheds
light on the more novel role of Smad4 in colorectal cancer, understanding the phenotype
of Smad4 mutations both in vivo and in vivo would provide invaluable information on
Smad4mut functions in tissues.
TGF-β controls cell growth by activating cyclin dependent kinase inhibitors (CDKIs)
such as p21 and p15 resulting in growth inhibition. Previous studies have demonstrated
that TGF-β growth inhibition is dependent on the presence of Smad4 171. In addition,
restoration of Smad4-WT in both human and murine CRC cell lines restores TGF-β
induced growth inhibition and reduces migration and invasion 172. This, along the data
presented in this thesis, would lead us to hypothesize that colorectal cancer cells
expressing Smad4 mutants will exhibit higher tumorigenicity, migration, and invasion
compared to their wild-type counterpart.
To determine the role of Smad4 mutations in CRC malignancy, we would use our
SW480, SW620 and HCT116 3:6 cells and perform WST-1 and BrdU incorporation
proliferation assays in the absence or presence of soluble TGF-β ligand. As a control, we
could treat cells with TGF-β receptor kinase (ALK5/TGFβRI) inhibitor SB431542167, which
would abrogate TGF-β signaling by blocking the receptor. We have some preliminary data
looking at cell migration and invasion in HCT116 3:6 cells (Fig 13A & B). HCT116 3:6 cells
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expressing Smad4-R361 mutation seem to have an intermediate migratory and invasive
phenotype compared to Smad4-null and Smad4-WT cells. In order to complement this
experiment, we could also perform a cell migration assay (in vitro wound healing assay).
As mentioned in the introduction to this thesis, TGF-β can induce epithelial to
mesenchymal transition (EMT) by inducing expression of EMT-promoting factors like
Snail, Slug, ZEB and Twist70. As EMT has been shown to be dependent on the presence
of Smad4173, we could look into the effect of Smad4-mutant on inducing these EMT
transcription factors. Investigating the details of how Smad4-mut expression is driving
epithelial-mesenchymal transition can help us better understand the role in EMT and
identifying how to prevent Smad4-mut from promoting this event in cancer patients.
Patients with mutant Smad4 have worse overall survival than patients with wildtype Smad4143. Our lab, as well as others, have extensively shown that downregulation of
Smad4-WT through shRNA leads to a higher incidence of primary tumors and metastasis
to the liver in mice81,83. Because all of the experiments proposed have been in vitro, we
could look into how these Smad4-mut phenotypes translate in an in vivo mouse model.
As orthotopic models accurately represent the progression and metastasis of CRC, we
could use an orthotopic cecal injection to evaluate the effect of Smad4 mutations on CRC
tumorigenicity and liver metastasis. Incidence of primary tumor formation would be
assessed by looking at the colon, while incidence of metastasis would be assessed by
looking in the liver. Taken together, these studies would allow us to understand whether
Smad4-mut promote CRC progression and whether it would make sense to block Smad4mut function in colorectal cancer patients.
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Figure 13. R361-mutant attenuates the inhibitor effect of Smad4 on cell migration
and invasion in HCT116 3:6 cells. The imagines of HCT116 3:6 cells are representative
of one pilot experiment (magnification 40X). Migration (A) and invasion (B) were
determined using transwell assays. The result of the quantification of cell migration and
invasion are shown (right).
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Effects of Smad4 mutations on other pathways in the TGF-β superfamily
As previously mentioned, TGF-β can activate both Smad and non-Smad signaling
pathways, such as Erk, JNK, and p38 MAPK kinase pathways39. Mehrvarz Sarshekeh et
al’s study revealed that patients with advanced disease observed a markedly shorter
progression-free survival time in patients with SMAD4-mutated tumors than in those wildtype for SMAD4 when treated with anti-epidermal growth factor receptor (EGFR)
treatment143. The fact that EGFR like cetuximab and panitumumab 27,28 is provided to
patients with wild-type KRAS (as any alterations in can lead to constitutive activation of
EGFR and ultimately to drug resistance28) suggests that mut-Smad4 may be affecting
other signaling pathways besides TGF-β.
To test this, we would need to use cell lines with wild type KRAS so that constitutive
active signaling of the pathway does not interfere with the interpretation of our results. The
tools to explore this, however, are limited given that most CRC cell lines harbor mutations
in KRAS gene (a reflection of patient data, where over half of CRC patients harbor
mutations in KRAS). There is one cell lines we could work with (COLO-320) that has wildtype KRAS and BRAF and baseline PI3K signaling. However, these cell lines express
endogenous Smad4 protein. We would need to 1) generate COLO-320 isogenic cell lines
using CRISPR-Cas9 to generate Smad4 KO clones and 2) re-introduce Smad4 retrovirally
(as we did in HCT116 3:6 cells). Due to the limitation of cell lines, we could also use an
organoid model system. By introducing inactivating mutations in APC, p53 and SMAD4
and activating KRAS(G12D) mutation, scientists have been able to use intestinal stem
cells to better model colorectal cancer in vitro and in vivo 174,175. In our case, we could use
this system to generate p53, APC and SMAD4 null organoids via CRISPR-Cas9, then
later introduce our Smad4 via retrovirus. As loss of SMAD4 has been shown to activate
downstream Akt and Erk signaling141,166,176, we can measure the levels of p-AKT and pERK in both Smad4-mut expressing cell lines and organoids. Overall, these observations
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would allow us to understand the effect of Smad4 R361-mutations on both other signaling
pathways in the TGF-β superfamily.

Investigating the mutSmad4-LEF1 axis in other cancers & diseases
It is worth investigating the mutSmad4-LEF1 signaling axis in other cancers, to
confirm the mechanism we have uncovered is conserved among other tumor types. This
will help us better understand how WNT signaling pathway could be used as a therapeutic
option for patients who have abnormalities in this pathway.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers
with a five-year survival of less than 5%87. Despite advancements in treatment and
therapies, mortality rates for PDAC patients still remains high. Over half of PDAC patients
with invasive disease have alterations in Smad4 protein 177, including deep deletions and
missense mutations. Studies have shown that loss or inactivation of SMAD4 is associated
with poor prognosis, due to an increased incidence of metastatic disease 178. In addition,
SMAD4 inactivating mutations occur in approximately 20% of all pancreatic cancer 92.
Similar to CRC tumors, they can occur in either MH1 or the MH2 domain, with the latter
resulting in either loss of protein stability or disruption of dimerization ability of the Smads.
One study has shown that missense mutations in SMAD4 at Y353C residue attenuates
the inhibitory effect of SMAD4 on cell migration and invasion in PDAC cells without
affecting cell proliferation 179. This suggests that missense mutations in Smad4 could affect
PDAC progression, just as we expect them to affect CRC progression.
According to cbioportal data, mutations in the R361 residue also are the most
frequent type of Smad4 missense mutation found in PDAC patients, as evidenced by their
lollipop plots (Figure 14A). In conclusion, understanding what the effect of R361-mutations
on PDAC patients are, and the mechanism whereby they can affect PDAC progression
can provide a firmer empirical basis for PDAC treatment.
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Apart from cancers, it would also be interesting to understand the role of mutant
Smad4 (and Smad4mut-LEF1 axis) in other diseases such as juvenile polyposis syndrome
(JPS). Juvenile polyposis syndrome (JPS) is an autosomal disease that is characterized
by the presence of benign polyps in the gastrointestinal tract, most commonly in the colon.
Patients with JPS have up to a 50% risk of developing specific types of cancer, including
colorectal (CRC) and other gastrointestinal (GI) malignancies 180,181. Similarly, familial
adenomatous polyposis (FAP) is a familial cancer predisposition syndrome with risk of
multiple cancer types, including 100% risk of colon cancer absent intervention. The
genetic basis of FAP is well-understood to be related to loss-of-function mutations,
deletions, or duplications in the APC gene, known to hyperactivate the WNT pathway182
This in turn leads to overexpression of the MYC oncogene and enhanced cell
proliferation183.
However, WNT pathway mutations have not been described in JPS. Instead, 3040% of JPS cases are associated with germline frameshift and missense mutations in
SMAD4 and BMPRIA receptor184. In CRC, SMAD4 pathway mutations (found with 1035% frequency) are known to be associated with such “late” events. However, how
SMAD4 mutations can contribute to polyp formation and increased cancer risk in JPS
patients remains unknown. Based on the work that we have done in our CRC cell lines,
we would hypothesize that germline SMAD4 missense mutations in JPS could promote
polyp formation by increasing WNT signaling. To test this, we would use CRISPR-Cas9
technology to knockout endogenous Smad4 in normal colon organoids and immortalized
colonocyte cell lines (NCM460, NCM365). We would then reconstitute them with naturally
occurring SMAD4 JPS variants (focusing on Smad4-R361H/C mutations) using
retroviral/lentiviral transduction. Once the JPS-associated Smad4 mutants (e.g.,
R361H/CS) are stably expressed, we would measure changes in WNT signaling by using
WNT-reporter activity assay (TOP/FOP luciferase). In addition, we could also test for
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different downstream signaling events correlated with WNT, such as activation of WNT
target genes like Axin2 and β-catenin and enhanced cell proliferation. Finally, we can
perform RNA-Seq on SMAD4-WT and SMAD4-mut cell lines and organoid, to compare
and contrast their transcriptomes. Because we would that expect that the presence of
SMAD4 missense mutations would correlate with enhanced reliance on this signaling
pathway, it would also be interesting to test the responses of patient derived organoids
and JPS-model cell lines with existing WNT inhibitors such as PRI-724 and ICG-001. Our
hypothesis is that mutations in Smad4 results in hyperactivation of WNT signaling, which
could provide direct molecular targets for therapeutic intervention. Identification of such
targets in JPS would be highly significant – and potentially translatable- development.

A

R361H/C/G

Figure 14. R361 mutation is prevalent in Smad4 in PDAC. (A) The prevalence and
spectrum of SMAD4 mutations in multiple pancreatic adenocarcinoma studies from
cbioportal.
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Identification of other proteins that might interact with mutSmad4
Protein-protein interactions are essential to the function of all proteins and define
their biological roles. Therefore, identification of protein binding partners can bring to light
important information about protein functions. One of the most practical and high-yielding
approaches is immunoprecipitation of a bait protein followed by mass spectrometry to
identify co-precipitating proteins. This technique has been done to identify novel binding
partners for mutations in other tumor suppressor genes, for example TP53. Some studies
have used mass spectrometry to demonstrate that mutant p53, but not p53 wild type, are
able to bind to novel proteins. For example, p53 R175H is able to bind to proteins Tim50
and MCM7185 and p53 R273H can bind NRD1 specifically186 . Thus, this method could be
useful in identifying novel protein-protein interactions or targets of mutant Smad4 as well.
Although proteomics analysis has been done in CRC cells with either Smad4-null
and Smad4 wild-type expressing cells187, no such experiments have been done with cells
expressing mutSmad4. To begin to investigate this, we could analyze the difference in
protein binding between wild-type Smad4 and mutant Smad4 via mass spectrometry
analysis. Because alteration at a single residue affects the binding of Smad4 to R-Smads,
it would be interesting to know it this mutation allows for other (yet unidentified) proteins
to bind to mutSmad4. If we wanted to further continue to study the role of mutSmad4 on
WNT signaling, we could do an alternate version of the experiment. We could pretreat the
cells with a WNT inhibitor and then send samples to mass spectrometry to identify proteins
that might bind differently to mutSmad4 in a WNT dependent manner. Once candidates
have been identified, we could test how the interaction of mutSmad4, and other proteins
affect either WNT signaling or any other signaling pathway that we choose to continue to
study. We could also test how the binding of these candidate proteins to mutSmad4 affects
their phenotype both in vitro and in vivo, which could help us further define on why
mutSmad4 (specifically R361 mutation) is so highly selected for in CRC cancer patients.
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SUMMARY AND CONCLUDING REMARKS
The work presented here demonstrated a novel, previously unidentified, function
for mutant Smad4 in CRC cells. We show that hotspot missense mutation in Smad4,
R361H/C is unable to bind to R-Smads, Smad2/3 or accumulate in the nucleus following
TGF-β treatment. In addition, Smad4-R361 mutants lose the ability to activate canonical
downstream TGF-β signaling. Although initially these R361 mutations seemed to behave
like loss of function mutations, we wanted to continue studying them given that they are
so highly selected for in CRC tumors, which is more consistent with a gain-of- or
neomorphic function. Following RNA-Sequencing, we were surprised to see that R361H
has a gene signature associated with upregulation of the TCF/LEF protein complex and
boosts downstream WNT signaling.
Having established that there is a gain of function role for Smad4 mutants, this
information can be used to develop peptide-based inhibitors targeting the interacting
domains between mutSmad4-LEF1, opening a therapeutic window for CRC patients
harboring Smad4-R361 mutations.
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